Though we found a consistently decreased immunogenic TME in ccRCC patients with PBRM1 loss across 5 patient cohorts, a previous Cas9-based screen in murine melanoma cells indicated that loss of PBRM1 may increase tumor immunogenicity24. Here, PBRM1 is linked to neoplasm.